2015 American Transplant Congress
Pharmacogenomic Predictors of Acute Rejection in Kidney Transplant Recipients Identified Using a DNA Biobank Linked to Electronic Medical Records
Purpose: Risk for acute rejection (AR) complicating transplant immunosuppression may be affected by frequent variants in pharmacogenes. Using a DNA biobank linked to electronic medical…2015 American Transplant Congress
Influence of POR*28 Genotype on Tacrolimus Disposition in Heart Transplant Recipients
Polymorphisms in P450 oxidoreductase (POR) have been shown to modulate CYP3A activity and alter the pharmacokinetics of CYP3A substrates, such as tacrolimus (TAC). The objective…2015 American Transplant Congress
Opportunities in Tacrolimus Therapeutic Drug Monitoring
Department of Pharmacy, NewYork-Presbyterian Hospital, NY.
Tacrolimus requires diligent therapeutic drug monitoring (TDM) to maintain appropriate serum concentrations after transplant. To optimize efficacy & minimize toxicity frequent levels are drawn, commonly…2015 American Transplant Congress
Prospective, 6 Month, Open Label, Conversion Study from Mycophenolate Mofetyl to Mycophenolic Acid Evaluating the Severity of Gastro-Intestinal Symptoms and Mycophenolic Acid Urinary Metabolite as a Surrogate Marker of Plasmatic Area Under the Curve
Introduction: Treatment with mycophenolate mofetil (MMF) often results in adverse gastro-intestinal (GI) events, which can lead to dose reductions that in turn can increase the…2015 American Transplant Congress
No Pharmacokinetic Interaction Between Pantoprazole and Mycophenolic Acid in Renal Transplant Patents: A Randomized Crossover Study
Department of Nephrology, Charité University Hospital, Berlin, Germany.
Mycophenolic acid (MPA) is used as an immunosuppressive agent in renal transplant (tx) patients (pts). 2 formulations are on the market: The prodrug Mycophenolate-Mofetil (MMF)…2015 American Transplant Congress
Does Infection Impact On Tacrolimus Blood Levels in Kidney Transplant Recipients?
Background Tacrolimus (Tac) is the cornerstone of immunosuppressive therapy in kidney transplant recipients. It is metabolized by members of the cytochrome p450 (CYP) 3A subfamily…2015 American Transplant Congress
Development and Validation of a Genotype Guided Tacrolimus Dosing Equation for African American (AA) Kidney Transplant Recipients
Tacrolimus (tac) has a strong exposure-response relationship with high inter-individual variability in troughs and dose. Tac dose requirements for AA patients are higher than Caucasians,…2015 American Transplant Congress
Pharmacokinetics of Everolimus (EVL) in Elderly Recipients Under Low-Tacrolimus(TAC)/Everolimus in the First Year After Renal Transplantation. Data from the NEverOLd Trial
Elderly ( >60 years) recipients are being renal transplanted more frequently. The pharmacokinetics studies (PK) of immunosuppressive drugs in healthy volunteers, rarely, if ever, include…2015 American Transplant Congress
Increasing Tacrolimus Exposure to Minumize Chronic Rejection: How Can We Do It? What Are the Risks?
Background: Recent studies suggest that increased tacrolimus (TAC) exposure may help prevent production of donor specific HLA antibodies (DSAs) that mediate chronic rejection of renal…2015 American Transplant Congress
Safety and Efficacy of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…
American Transplant Congress abstracts